Stock Market Reviews

ALGS (Aligos Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ALGS (Aligos Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employ
  Dec 12, 2025 - $ALGS
• Aligos Therapeutics Presents Positive Data at HEP-DART 2025
  Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from four presentations, including two oral presentations, at the HEP-DART 2025 Me
  Dec 11, 2025 - $ALGS
• Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 23,600 shares of the Company’s stock (the “Inducement Grant”) to newly hired employ
  Nov 14, 2025 - $ALGS
• Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
  Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of
  Nov 10, 2025 - $ALGS
• Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
  SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China
  Nov 6, 2025 - $ALGS
• Aligos Therapeutics to Present at Upcoming Investor Conferences
  SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences. Jefferies London Healthcare Conference Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT Piper Sandler 37th Annual Healthcare Conference Fireside Chat o
  Nov 4, 2025 - $ALGS
• Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
  SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical
  Oct 30, 2025 - $ALGS
• Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
  SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection. The USAN, cons
  Oct 16, 2025 - $ALGS
• Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
  SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright Liver Disease Conference being held October 21 - 22, 2025. A webcast of the presentation will be accessible by visiting the Presentation & Events section on the “Investors”
  Oct 14, 2025 - $ALGS
• Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
  Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting® 2025, being held November 7 –
  Oct 7, 2025 - $ALGS